EUVIMEDEUVIMED entdecken
Open Access

Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California

Kelly C Young-Wolff iD, Natalie Slama iD, Stacey E Alexeeff, Lori C Sakoda, Renee Fogelberg, Laura C Myers, Cynthia I Campbell, Alyce S Adams, Judith J Prochaska iD

Nicotine & Tobacco Research · 2023

DOI: 10.1093/ntr/ntac090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nicotine & Tobacco Research, 2023. Verfasst von Kelly C Young-Wolff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Hauptthemen laut MEDLINE: COVID-19, Delivery of Health Care, Integrated. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIDDK NIH HHS, Tobacco-Related Disease Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The relationship between tobacco smoking status and SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) severity is highly debated. We conducted a retrospective cohort study of >2.4 million adults in a large healthcare system to evaluate whether smoking is associated with SARS-CoV-2 infection and disease severity. Aims and Methods This retrospective cohort study of 2,427,293 adults in KPNC from March 5, 2020 (baseline) to December 31, 2020 (pre-vaccine) included smoking status (current, former, never), socio-demographics, and comorbidities from the electronic health record. SARS-CoV-2 infection (identified by a positive PCR test) and COVID-19 severity (hospitalization, ICU admission or death ≤ 30 days of COVID-19 diagnosis) were estimated in time-to-event analyses using Cox proportional hazard regression models adjusting for covariates. Secondary analyses examined COVID-19 severity among patients with COVID-19 using logistic regression.

Results

During the study, 44,270 patients had SARS-CoV-2 infection. Current smoking was associated with lower adjusted rates of SARS-CoV-2 infection (aHR = 0.64 95% CI: 0.61–0.67), COVID-19-related hospitalization (aHR = 0.48 95% CI: 0.40–0.58), ICU admission (aHR = 0.62 95% CI: 0.42–0.87), and death (aHR = 0.52 95% CI: 0.27–0.89) than never-smoking. Former smoking was associated with a lower adjusted rate of SARS-CoV-2 infection (aHR = 0.96 95% CI: 0.94–0.99) and higher adjusted rates of hospitalization (aHR = 1.10 95% CI: 1.03–1.08) and death (aHR = 1.32 95% CI: 1.11–1.56) than never-smoking. Logistic regression analyses among patients with COVID-19 found lower odds of hospitalization for current versus never-smoking and higher odds of hospitalization and death for former versus never-smoking.

Conclusions

In the largest US study to date on smoking and COVID-19, current and former smoking showed lower risk of SARS-CoV-2 infection than never-smoking, while a history of smoking was associated with higher risk of severe COVID-19.

Implications

In this cohort study of 2.4 million adults, adjusting for socio-demographics and medical comorbidities, current tobacco smoking was associated with a lower risk of both SARS-CoV-2 infection and severe COVID-19 illness compared to never-smoking. A history of smoking was associated with a slightly lower risk of SARS-CoV-2 infection and a modestly higher risk of severe COVID-19 illness compared to never-smoking. The lower observed COVID-19 risk for current versus never-smoking deserves further investigation. Results support prioritizing individuals with smoking-related comorbidities for vaccine outreach and treatments as they become available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Delivery of Health Care, IntegratedHumansAdultCOVID-19 TestingCohort StudiesRetrospective StudiesSARS-CoV-2Tobacco SmokingCaliforniaPatient AcuityHospitalization

Autor:innen und Institutionen

  • Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
  • Richmond Medical Center, Kaiser Permanente Northern California, Richmond, CA, USA.
  • Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Stanford Prevention Research Center, Stanford University, Stanford, CA, USA.

ORCID-Profile: Kelly C Young-Wolff, Natalie Slama, Judith J Prochaska

Förderung

  • NIDA NIH HHS
  • NIDDK NIH HHS
  • Tobacco-Related Disease Research Program
  • NIH
  • National Institute on Drug Abuse

Zitieren

APA

Young-Wolff, K. C., Slama, N., Alexeeff, S. E., Sakoda, L. C., Fogelberg, R., Myers, L. C., Campbell, C. I., Adams, A. S., & Prochaska, J. J. (2023). Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California. Nicotine & Tobacco Research. https://doi.org/10.1093/ntr/ntac090

Vancouver

Young-Wolff KC, Slama N, Alexeeff SE, Sakoda LC, Fogelberg R, Myers LC, et al. Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California. Nicotine & Tobacco Research. 2023. doi:10.1093/ntr/ntac090

BibTeX
@article{YoungWolff2023,
  author = {Young-Wolff, Kelly C and Slama, Natalie and Alexeeff, Stacey E and Sakoda, Lori C and Fogelberg, Renee and Myers, Laura C and Campbell, Cynthia I and Adams, Alyce S and Prochaska, Judith J},
  title = {Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California},
  journal = {Nicotine & Tobacco Research},
  year = {2023},
  doi = {10.1093/ntr/ntac090}
}
Kostenlos starten →